Nav: Home

Aggressive care at end of life for advanced lung cancer patients linked to poorer outcomes

May 25, 2017

PHILADELPHIA (May 25, 2017) - For patients with advanced cancer, aggressive care -- chemotherapy, mechanical ventilation, acute hospitalizations and intensive care unit admissions -- at the end of life is commonplace. Yet until now, little is known about the relationship between patients' and families' satisfaction with this aggressive care within the last 30 days of life.

A new study, from the Department of Veterans Affairs and University of Pennsylvania School of Nursing (Penn Nursing), suggests that such care is not likely to contribute positively to patients' and families' experiences in the final days of life. Furthermore, the study results support the view that aggressive care at the end of life for patients with advanced cancer is an indicator of poor-quality end-of-life care. The findings of the study are set for publication in an upcoming issue of the journal Cancer. A digital version of the study has been published online first and is accessible here. The study was conducted by an interdisciplinary group of investigators led by Mary Ersek, PhD, RN, FPCN, who holds a joint appointment at the Department of Veterans Affairs and Penn Nursing, and Vince Mor, PhD, from Brown University and the Providence VA Medical Center.

The researchers examined the care and outcomes for 847 Veterans with non-small cell lung cancer who died in a VA inpatient setting from 2010-2012. The study described rates of aggressive care and the association of aggressive care with bereaved families' evaluations of care in the final month of life. The investigators found that almost three-quarters of the sample had at least one episode of aggressive care in the last 30 days of life, which they defined as receipt of injectable chemotherapy or mechanical ventilation, or more than two hospitalizations or admission to an intensive care unit. These high rates of aggressive care were not associated with younger age. However, they may have reflected the VA's adoption of "concurrent care," which, unlike Medicare, allows patients to receive disease-modifying treatments along with hospice/palliative care.

The results also show that for Veterans dying in acute care or nursing home settings, aggresse care was associated with lower overall ratings of care than when patients did not have any aggressive care. However, for patients dying in VA inpatient hospice units, the difference in outcomes were not significant between patients receiving aggressive care and those who did not receive any aggressive care.

"It is important to give patients with advanced illness options for care, including concurrent care. However, we need to be mindful that aggressive care at the end of life is not associated with better patient outcomes, and guide patients accordingly," said Ersek. "Regardless of the treatment that patients choose, we need to be offering hospice and palliative care services."
-end-
This research was supported by a grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research Development, Health Services Research and Development Service 1I01HX000956-01. Mor is the principal investigator of the study and Ersek serves as a co-investigator.

About the Corporal Michael J. Crescenz VA Medical Center

The Corporal Michael J. Crescenz VA Medical Center provides health care to Veterans living in America's fifth-largest metropolitan area, including the city of Philadelphia and six surrounding counties in Southeastern Pennsylvania and Southern New Jersey. The Crescenz VAMC is part of the VA Healthcare Network - VISN4 and serves as an acute referral center for VA health care facilities in eastern Pennsylvania, Delaware and Southern New Jersey.

About the University of Pennsylvania School of Nursing

The University of Pennsylvania School of Nursing is one of the world's leading schools of nursing. For the second year in a row, it is ranked the #1 nursing school in the world by QS University, and has four graduate programs ranked number one by U.S. News & World Report, the most of any school in the United States. Penn Nursing is consistently among the nation's top recipients of nursing research funding from the National Institutes of Health. Penn Nursing prepares nurse scientists and nurse leaders to meet the health needs of a global society through research, education, and practice. Follow Penn Nursing on: Facebook, Twitter, LinkedIn, Instagram & YouTube.

University of Pennsylvania School of Nursing

Related Chemotherapy Articles:

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.
Male fertility after chemotherapy: New questions raised
Professor Delbès, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.
'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.
Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.
Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.
A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.
Chemotherapy or not?
Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how 'smart' diagnostic-imaging machines identify cancers -- and uncovering clues outside the tumor to tell whether a patient will respond well to chemotherapy.
Researchers use radiomics to predict who will benefit from chemotherapy
Using data from computed tomography (CT) images, researchers may be able to predict which lung cancer patients will respond to chemotherapy, according to a new study.
How drugs can minimize the side effects of chemotherapy
Researchers at the University of Zurich have determined the three-dimensional structure of the receptor that causes nausea and vomiting as a result of cancer chemotherapy.
More Chemotherapy News and Chemotherapy Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.